Clinical Pipeline


ADXS-cHER2 Clinical Program

ADXS-cHER2 is currently in pre-clinical development for the treatment of HER2 over-expressing human cancers, including breast cancer.

ADXS-cHER2 is an immunotherapy that is under investigation for targeting HER2 over-expressing cancers. The antigen in ADXS-cHER2 is a combination antigen, combining two external and three internal binding epitopes of the HER-2 peptide into a truncated combination peptide fused to truncated LLO. By incorporating HER2 into the Advaxis live, attenuated vector, Advaxis is studying the delivery of the HER2 antigen fused to the immunostimulant LLO, directly inside antigen presenting cells that are believed to drive a cellular immune response to HER2 over-expressing cells. The Advaxis approach is being researched for the inhibition of Treg and MDSC cells specifically in the tumors that have been promoting immunologic tolerance of the cancer.